| P2093 | author name string | Jian Cao | |
| | Stanley Zucker | |
| | Kaushik Doshi | |
| P2860 | cites work | Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK | Q22004018 |
| | A matrix metalloproteinase expressed on the surface of invasive tumour cells | Q24312733 |
| | MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes | Q24628843 |
| | Collagenolytic activity in amphibian tissues: a tissue culture assay | Q24648397 |
| | Aggrecanases and cartilage matrix degradation | Q24804310 |
| | Matrix metalloproteinases | Q28140451 |
| | Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization | Q28145656 |
| | Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease | Q28195331 |
| | Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) | Q28204521 |
| | Gelatinase B deficiency protects against endotoxin shock | Q28220536 |
| | Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer | Q28278066 |
| | Matrix metalloproteinases: effectors of development and normal physiology | Q28679038 |
| | New functions for the matrix metalloproteinases in cancer progression | Q29547738 |
| | How matrix metalloproteinases regulate cell behavior | Q29620360 |
| | Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome | Q31928168 |
| | Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 |
| | Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing | Q33910089 |
| | Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques | Q34327535 |
| | TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma | Q73082328 |
| | Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis | Q73168842 |
| | Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome | Q73187372 |
| | Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis | Q73202289 |
| | Differential release of matrix metalloproteinase‐9 and nitric oxide following infusion of endotoxin to human volunteers | Q73267520 |
| | Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2 | Q73288795 |
| | Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis | Q73294428 |
| | Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma | Q73365261 |
| | Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease | Q73378459 |
| | In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer | Q73394995 |
| | Determining the levels of matrix metalloproteinase-9 in portal and peripheral blood is useful for predicting liver metastasis of colorectal cancer | Q73537414 |
| | Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy | Q73543421 |
| | Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy | Q73580710 |
| | Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis | Q73678542 |
| | Changes in serum concentrations of matrix metalloproteinases in kidney transplantation | Q73794798 |
| | Matrix metalloproteinases as novel disease markers in Takayasu arteritis | Q73894492 |
| | Gelatinase isoforms in urine from bladder cancer patients | Q74016740 |
| | Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension | Q74292680 |
| | Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in postoperative biliary atresia patients | Q74336757 |
| | Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer | Q74351295 |
| | Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis | Q74462473 |
| | Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy | Q74588037 |
| | Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis | Q74610831 |
| | Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer | Q74774814 |
| | Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis | Q74819688 |
| | Abnormalities of the extracellular degradation of collagen type I in essential hypertension | Q77133088 |
| | Prenatal plasma matrix metalloproteinase-9 levels to predict spontaneous preterm birth | Q77168019 |
| | Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340) | Q77300084 |
| | Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities | Q77301214 |
| | Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma | Q77332036 |
| | Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C | Q77369404 |
| | Effect of cigarette smoking on plasma metalloproteinase-9 concentration | Q77386141 |
| | Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis | Q77493631 |
| | Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment | Q77695340 |
| | Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus | Q77723474 |
| | Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty | Q77738040 |
| | Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms | Q77773046 |
| | A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels | Q77922288 |
| | Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease | Q78001306 |
| | Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas | Q78319848 |
| | Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip | Q78387198 |
| | Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis | Q78531410 |
| | Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis | Q78560074 |
| | MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome | Q78571232 |
| | Effects of blood collection methods on gelatin zymography of matrix metalloproteinases | Q78863411 |
| | Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings | Q79108018 |
| | Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. | Q34542211 |
| | Proteomic applications for the early detection of cancer | Q35097366 |
| | Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials | Q35144569 |
| | Evidence for altered hepatic matrix degradation in genetic haemochromatosis | Q35350790 |
| | Activity of type IV collagenases in benign and malignant breast disease | Q35976755 |
| | Serum metalloproteinases and their inhibitors: markers for malignant potential | Q36079649 |
| | Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid | Q36401533 |
| | Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer | Q36617818 |
| | Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. | Q36836819 |
| | Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction | Q36847959 |
| | Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine | Q37246271 |
| | Basic principles of ROC analysis | Q39680201 |
| | Matrix metalloproteinases and cardiovascular disease | Q40410789 |
| | Structural features of a superfamily of zinc-endopeptidases: the metzincins | Q40428339 |
| | Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease | Q40596987 |
| | Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. | Q40607050 |
| | Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis | Q40640392 |
| | Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment | Q40642347 |
| | Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. | Q40686965 |
| | Alcohol and the liver: 1994 update. | Q40733804 |
| | Proteolytic remodeling of extracellular matrix | Q40952583 |
| | Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic | Q41084451 |
| | Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex | Q41580840 |
| | A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. | Q41598897 |
| | Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. | Q42487674 |
| | Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response | Q42981834 |
| | Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma | Q43534133 |
| | Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress | Q43649151 |
| | Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis | Q43659456 |
| | Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis | Q43904329 |
| | Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. | Q43937949 |
| | Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy | Q44264767 |
| | Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction | Q44294980 |
| | Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure | Q44514122 |
| | TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism | Q44530445 |
| | Human gelatinase/type IV procollagenase is a regular plasma component | Q45732577 |
| | The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. | Q47204940 |
| | Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study | Q47337393 |
| | Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes | Q47671940 |
| | Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc | Q47817151 |
| | Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? | Q48006505 |
| | Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study | Q48267716 |
| | Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease | Q48339188 |
| | Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain | Q48384389 |
| | Unriddling the role of matrix metalloproteinases in human cerebral stroke | Q48413194 |
| | Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients | Q48744549 |
| | Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor alpha release during cardiopulmonary bypass | Q49110720 |
| | The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. | Q50664883 |
| | Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. | Q50675260 |
| | Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. | Q50849840 |
| | Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. | Q50862383 |
| | Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. | Q52900472 |
| | Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. | Q52973689 |
| | Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. | Q53000471 |
| | Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. | Q53885661 |
| | Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. | Q55475255 |
| | Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma | Q57758506 |
| | Matrix metalloproteinases and their inhibitors in acute viral hepatitis | Q58239693 |
| | Circulating levels of matrix metalloproteinases in heart transplant recipients | Q58621956 |
| | Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure | Q59192141 |
| | Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood | Q62632545 |
| | Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer | Q62632579 |
| | Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects | Q62632586 |
| | Serum collagenase levels in relation to the state of the human cervix during pregnancy and labor | Q67586450 |
| | Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma | Q67969304 |
| | 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer | Q70842383 |
| | Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon | Q71068620 |
| | Proteases and their inhibitors are indicative in gestational disease | Q71716172 |
| | Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases | Q71757372 |
| | Increased levels of stromelysin‐1 and tissue inhibitor of metalloproteinases–1 in sera from patients with rheumatoid arthritis | Q71880224 |
| | Levels of circulating collagenase, stromelysin‐1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis: relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation | Q71970867 |
| | Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases | Q72002727 |
| | Tissue inhibitor of metalloproteinases: serum levels during pregnancy and labor, term and preterm | Q72306165 |
| | A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies | Q72344460 |
| | Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays | Q72722726 |
| | A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats | Q72853153 |
| | Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis | Q72871588 |
| | Matrix metalloproteinase-1 and cytokines in patients with acute pancreatitis | Q73045472 |
| | MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover | Q73082300 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 37-85 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Advances in Clinical Chemistry | Q15757020 |
| P1476 | title | Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications | |
| P478 | volume | 38 | |